PURPOSE: Because as many as 30% of cancer patients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’ perceived knowledge gaps, barriers,and educational interests relevant to CINV. METHODS: An Internet-based survey was developed and was electronically disseminated to members of Medscape, an international Internet-based continuing medical education provider. RESULTS: A total of 2388 health care providers responded to the survey. Although breakthrough nausea and vomiting was the most common CINV-related issue they managed in the preceding year, managing delayed nausea was the most problematic in that time period. Thirty-two percent of health care providers delayed or discontinued a patient’s chemotherapy because of CINV. Cost of antiemetics, patients’ poor adherence to antiemetic regimens, and health care providers’ underestimation of risk for CINV were all barriers to effective management. Health care providers expressed a wide range of educational interests, including managing breakthrough CINV, keeping up with novel antiemetic agents, and learning about emerging approaches for CINV prevention/management. CONCLUSIONS: This survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancer patients at risk for or suffering from CINV.
PURPOSE: Because as many as 30% of cancerpatients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’ perceived knowledge gaps, barriers,and educational interests relevant to CINV. METHODS: An Internet-based survey was developed and was electronically disseminated to members of Medscape, an international Internet-based continuing medical education provider. RESULTS: A total of 2388 health care providers responded to the survey. Although breakthrough nausea and vomiting was the most common CINV-related issue they managed in the preceding year, managing delayed nausea was the most problematic in that time period. Thirty-two percent of health care providers delayed or discontinued a patient’s chemotherapy because of CINV. Cost of antiemetics, patients’ poor adherence to antiemetic regimens, and health care providers’ underestimation of risk for CINV were all barriers to effective management. Health care providers expressed a wide range of educational interests, including managing breakthrough CINV, keeping up with novel antiemetic agents, and learning about emerging approaches for CINV prevention/management. CONCLUSIONS: This survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancerpatients at risk for or suffering from CINV.
Authors: John M Salsman; Steven M Grunberg; Jennifer L Beaumont; Miriam Rogers; Diane Paul; Marla L Clayman; David Cella Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman Journal: J Natl Cancer Inst Date: 2014-03-13 Impact factor: 13.506
Authors: Ralph Boccia; Steven Grunberg; Edwin Franco-Gonzales; Edward Rubenstein; Daniel Voisin Journal: Support Care Cancer Date: 2013-01-26 Impact factor: 3.603
Authors: Andrea Tendas; Pasquale Niscola; Alessio Perrotti; Teresa Dentamaro; Paolo de Fabritiis; William Arcese Journal: Support Care Cancer Date: 2015-03-28 Impact factor: 3.603
Authors: Pascale Dielenseger; Sussanne Börjeson; Cheryl Vidall; Annie Young; Patrick Jahn Journal: Support Care Cancer Date: 2019-02-19 Impact factor: 3.603
Authors: Tito Borner; Evan D Shaulson; Misgana Y Ghidewon; Amanda B Barnett; Charles C Horn; Robert P Doyle; Harvey J Grill; Matthew R Hayes; Bart C De Jonghe Journal: Cell Metab Date: 2020-01-09 Impact factor: 27.287
Authors: Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons Journal: Support Care Cancer Date: 2017-03-09 Impact factor: 3.603
Authors: Bernardo Rapoport; Daniel Chua; Allen Poma; Sujata Arora; Yan Wang; Luis Enrique Fein Journal: Support Care Cancer Date: 2015-05-05 Impact factor: 3.603